Immunotherapy as First Line therapy in Cancer Treatment: A Chemotherapy Sparing Regimen?
Executive Summary Immunotherapy has emerged as a transformative approach in oncology, leveraging the body’s immune system to combat cancer. As a first-line therapy, immunotherapy—either alone or in combination with other modalities such as chemotherapy or targeted therapies—has gained regulatory approval for various cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma. By harnessing immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and emerging modalities like cancer vaccines, immunotherapy offers durable responses and improved survival outcomes for select patient populations. This white paper explores the current landscape, clinical applications, benefits, challenges, and future directions of immunotherapy as a first-line treatment in cancer care. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, necessitating innovative therapeutic strategies. Immu...